Conduit Pharmaceuticals- Warrants (22/09/2028) Receivables

The latest receivables for CDTTW is $500M as of March 2026. That compares with $420M in the prior-year period — up 18.8% year over year. Investors often review this figure alongside Conduit Pharmaceuticals- Warrants (22/09/2028)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, CDTTW's receivables moved from $420M to $500M — a 18.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Conduit Pharmaceuticals- Warrants (22/09/2028)'s operating scale or balance-sheet position.

A receivables figure of $500M for CDTTW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting CDTTW's receivables ($500M), review year-over-year change from $420M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.